IBI-322
Product Specifications
Target
PD-1/PD-L1, Others
Related Pathways
Apoptosis, Others, Immunology/Inflammation, Cell Cycle/Checkpoint
Bioactivity
IBI-322 is a bispecific antibody targeting PD-L1 and CD47. In monovalent binding, it can attenuate the activity of CD47, and in bivalent binding, it can block the activity of PD-L1. IBI-322 selectively binds to CD47+PD-L1+ tumor cells, effectively inhibiting the CD47-SIRPα signaling and inducing strong tumor cell phagocytosis in vitro.
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
A1125-13F-APC 100 µL
Akt1 (v-akt Murine Thymoma Viral Oncogene Homolog 1, C-AKT, MGC99656, Oncogene AKT1, PRKBA, Protein Kinase B, PKB, RAC, RAC-ALPHA, RAC-alpha serine/threonine-protein kinase, RAC-PK-alpha) (APC) discontinued
Sign In for Pricing
View Details 
GTR15156975 1 Vial
Lentiviral mouse Mus81 shRNA (UAS) - Lentiviral mouse Mus81 shRNA (UAS, iRFP) (100)
Sign In for Pricing
View Details